Hybio Pharmaceutical Co., Ltd. (SHE:300199)

China flag China · Delayed Price · Currency is CNY
23.65
-0.27 (-1.13%)
May 20, 2026, 11:35 AM CST
Market Cap21.13B +86.1%
Revenue (ttm)955.53M +27.4%
Net Income94.52M
EPS0.10
Shares Out883.24M
PE Ratio233.88
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,699,046
Average Volume54,109,043
Open23.00
Previous Close23.92
Day's Range22.85 - 24.02
52-Week Range13.46 - 31.19
Beta0.76
RSI63.65
Earnings DateApr 29, 2026

About Hybio Pharmaceutical

Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally. The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix and atosiban for obstetrics and gynecology, etc; customized peptides; working standards for the peptide APIs and related impurities, to facilitate your project in an all-round way; CRO services; ... [Read more]

Sector Healthcare
Founded 1998
Employees 1,035
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300199
Full Company Profile

Financial Performance

Financial Statements